But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets ...

Lotte Biologics Co., the biotech arm of Lotte Group, said Thursday it has signed a deal with an Asia-based biotech company ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Keymed Biosciences’ CM518D1, a CDH17-targeted ADC receives IND approval from China NMPA to treat solid tumours: Chengdu, China Monday, April 28, 2025, 15:00 Hrs [IST] Keymed Bio ...

"IL1RAP is an attractive target from an ADC perspective and the data presented show that conjugation of a toxic payload to an anti-IL1RAP antibody has strong potential as a safe and effective anti ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for ...

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today ...

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago Debiopharm announces oral and poster presentations ...

LUND, SWEDEN / ACCESS Newswire / April 25, 2025 / Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today released a poster with new preclinical data that strengthens the rationale behind the ...